# Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

> **NCT00072722** · PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 36 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** CC-4047

## Key facts

- **NCT ID:** NCT00072722
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 36 (—)
- **Last updated:** 2006-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072722, "Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00072722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*